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Background: Recent data suggest that intensity-modulated radiation therapy (IMRT) 
plus brachytherapy boost for unfavorable prostate cancer provides improved biochem-
ical relapse-free survival over IMRT alone. Stereotactic body radiation therapy (SBRT) 
may be a less invasive alternative to brachytherapy boost. Here, we report the 3-year 
gastrointestinal (GI) and genitourinary (GU) toxicities of IMRT plus SBRT boost.
Materials and methods: Between March 2008 and September 2012, patients with 
prostate cancer were treated with robotic SBRT (19.5 Gy in three fractions) followed by 
fiducial-guided IMRT (45–50.4 Gy) on an institutional protocol. Toxicity was prospectively 
graded using the common terminology criteria for adverse events version 4.0 (CTCAEv.4) 
at the start of and at 1- to 6-month intervals after therapy. Rectal telangiectasias were 
graded using the Vienna Rectoscopy Score (VRS).
results: At a median follow-up of 4.2 years (2.4–7.5), 108 patients (4 low-, 45 inter-
mediate-, and 59 high-risk) with a median age of 74 years (55–92) were treated with 
SBRT plus IMRT, with 8% on anticoagulation and an additional 48% on antiplatelet 
therapy at the start of therapy. The cumulative incidence of late ≥grade 2 GI toxicity 
was 12%. Of these, 7% were due to late rectal bleeding, with six patients requiring up 
to two coagulation procedures. One patient with rectal telangiectasias was treated with 
Abbreviations: 3D-CRT, 3D-conformal radiation therapy; ADT, androgen deprivation therapy; APC, argon plasma coagula-
tion; CCI, Charlson comorbidity index; CTC, common terminology criteria; CTCAEv.4, common terminology criteria for 
adverse events version 4.0; CTV, clinical target volume; DVH, dose–volume histogram; ECE, extracapsular extension; EBRT, 
external beam radiation therapy; EPIC-26, expanded prostate cancer index composite-26; GI, gastrointestinal; GU, genitou-
rinary; HBO, hyperbaric oxygen; HDR, high dose rate; IGRT, image-guided radiation therapy; IMRT, intensity-modulated 
radiation therapy; LDR, low dose rate; MRI, magnetic resonance imaging; NCI, National Cancer Institute; NPO, Non-Per 
Os; OAR, organs at risk; PSA, prostate-specific antigen; PTV, planning target volume; QOL, quality of life; RTOG, Radiation 
Therapy Oncology Group; SBRT, stereotactic body radiation therapy; SIB, simultaneous integrated boost; TURP, transurethral 
resection of the prostate; VMAT, volumetric arc therapy; VRS, Vienna Rectoscopy Score.
2Paydar et al. Prostate Cancer SBRT Boost Toxicity
Frontiers in Oncology | www.frontiersin.org February 2017 | Volume 7 | Article 5
inTrODUcTiOn
Prostate cancer is the most common malignancy in men in the 
United States, with an estimated 220,800 men diagnosed in 2015 
(1). Of these patients, approximately 15% present with high-risk 
disease (2). Radiotherapy is the mainstay for treatment of such 
patients, and several randomized prospective trials have dem-
onstrated that dose-escalated radiotherapy results in improved 
biochemical-free survival (3–5). Further improvements have also 
been achieved with the advent of image-guided radiation therapy 
(IGRT) (6) and low dose rate (LDR) brachytherapy boost (7, 8).
Recent clinical data have demonstrated that large radiation 
fraction sizes likely confer a radiobiologic advantage in the set-
ting of prostate adenocarcinoma (9), thus providing the rationale 
for high dose rate (HDR) brachytherapy as a boost to external 
beam radiation therapy (EBRT) for intermediate- and high-risk 
patients. Several institutional series have reported favorable 
outcomes, with biochemical control rates of 87–88 and 69% at 
5–7  years for intermediate- and high-risk disease, respectively 
(10–13). These results have subsequently been confirmed in 
randomized trials (14, 15). Not surprisingly, such cancer control 
outcomes present with an increased risk of clinically significant 
long-term genitourinary (GU) toxicities such as urethral stricture 
(16–18).
In an effort to maximize the benefit of administering high 
doses per fraction and patient acceptance, we have examined the 
use of stereotactic body radiation therapy (SBRT) as a prostatic 
boost to image-guided intensity-modulated radiation therapy 
(IMRT) for the treatment of patients with unfavorable clinically 
localized prostate cancer. Previously, we reported early outcomes 
of this treatment modality, with a 3-year biochemical-free sur-
vival rate of 100% for intermediate-risk and 89.8% for high-risk 
disease (19). Similarly, we reported that such a therapy conferred 
minimal impact on long-term quality of life (QOL) (19). Several 
other studies have supported our early results (20–23). Here, we 
report the 3-year gastrointestinal (GI) and GU toxicity from this 
therapy.
MaTerials anD MeThODs
Patient selection
Patients with histologically confirmed adenocarcinoma of the 
prostate were included in the study. Exclusion criteria included 
clinically involved lymph nodes, bone metastases, or prior pelvic 
radiotherapy. Androgen deprivation therapy (ADT) was consid-
ered for all intermediate- and high-risk patients and ultimately 
was administered at the discretion of the treating physicians. 
The MedStar Health Research Institute-Georgetown University 
Oncology Institutional Review Board approved this study. 
This research study was carried out under a continuing review 
approved by this Institutional Review Board (IRB#2009-510). 
Continuing review is in accordance with institutional guidelines 
and was approved though expedited review by the IRB Chair or 
designee on 1/8/2016. The informed consent requirement was 
waived by the Committee that approved the study, and all data 
used in this study were anonymized.
sBrT Treatment Planning and Delivery
All patients had four or more gold fiducials placed in the 
prostate prior to treatment planning. To allow for fiducial 
stabilization, planning images were obtained a minimum of 
7  days after fiducial placement. Patients underwent magnetic 
resonance imaging (MRI) followed shortly thereafter by a thin 
cut (1.25 mm) CT scan. For the few patients with contraindica-
tions to MRI, CT-urethrogram was employed as an alternative 
imaging approach to identify the location of the prostatic apex 
(24). Both scans were performed with an empty bladder. Patients 
were advised to adhere to a low-gas, low-motility diet starting at 
least 5 days prior to all treatment planning imaging and treatment 
delivery. They were also instructed to remain nothing by mouth 
(Non-Per Os) for at least 4 hours prior to imaging as well as SBRT 
treatment. An enema was administered 1–2 hours prior to imag-
ing and SBRT treatment.
CT and MR images were fused for treatment planning. The 
clinical target volume (CTV) included the prostate, areas of 
radiographic extracapsular extension (ECE), and the proximal 
seminal vesicles to the point of separation. Pelvic lymph nodes 
were not included in the CTV. The SBRT planning target 
volume 1 (PTV1) equaled the CTV expanded 3 mm posteriorly 
and 5  mm in all other dimensions. The prescription dose was 
19.5 Gy to the PTV1 delivered in three fractions of 6.5 Gy over 
3–5  days. The prescription isodose line was limited to ≥75%, 
which limited the maximum prostatic urethra dose to 133% 
of the prescription dose. The rectum, bladder, penile bulb, and 
membranous urethra were contoured and evaluated with dose–
volume histogram (DVH) analysis during treatment planning 
hyperbaric oxygen (grade 3 toxicity). No rectal fistulas or stenoses were observed. Ten 
patients had multiple non-confluent telangiectasias (VRS grade 2), and three patients 
had multiple confluent telangiectasias (VRS grade 3). The cumulative incidence of late 
grade 3 GU toxicity was 6%. Most late toxicities were due to hematuria requiring bladder 
fulguration. There were no late ≥grade 4 GU toxicities.
conclusion: Rates of clinically significant GI and GU toxicities are modest following 
IMRT plus SBRT boost. Future studies should compare cancer control, quality of life, 
and toxicity with other treatment modalities for patients with high-risk prostate cancer.
Keywords: prostate cancer, sBrT, iMrT, cyberKnife, common terminology criteria
FigUre 1 | example of radiobiologically equivalent dose–volume histogram (DVh) of a patient with late grade 2 rectal bleeding treated with two 
argon plasma coagulations and no genitourinary toxicity.
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using Multiplan (Accuray Inc., Sunnyvale, CA, USA) inverse 
treatment planning. Less than 1 cc of the rectum and less than 
10 cc of the bladder were to receive 19.5 Gy. Less than 50% of 
the membranous urethra was to receive 18 Gy. Further details on 
dose and volume constraints to the critical structures have been 
previously described (19, 25).
intensity-Modulated radiation Therapy
Patients initiated IMRT treatment the week following SBRT. 
The more generous planning target volume 2 (PTV2) included 
a margin of 1.0 cm around the CTV except at the rectal interface 
where a margin of 0.5 cm was added. Daily doses of 1.8 Gy were 
delivered to the PTV2 5 days a week to a total dose of 45–50.4 Gy 
in 25–28 fractions. One-hundred percent of the PTV2 was to 
receive at least 95% of the prescription dose, and 5% of the volume 
was to receive no more than 105% of the prescription dose. For 
the bladder and rectum, the maximum dose constraint limit was 
50 Gy, the full-volume dose constraint limit was 30 Gy, and no 
part of either volume received more than 55.5 Gy. Dose to the 
femoral heads was limited to 45 Gy.
linear-Quadratic Transformation of a 
sample combined Physical iMrT Plus 
sBrT Boost DVh to a radiobiologically 
equivalent DVh
A radiobiologically equivalent dose DVH was generated by add-
ing doses in 2 Gy equivalents for IMRT and SBRT plans from a 
sample patient (26). Cumulative DVHs were extracted from the 
treatment planning software and converted to radiobiologically 
equivalent DVHs using MIM software (MIMvista Corporation, 
Cleveland, OH, USA). An α/β ratio of 1.5 was utilized to transform 
target volume doses (CTV and PTV), and an α/β ratio of 3 was 
used to transform doses for all other organs at risk. Combination 
of radiobiologically equivalent DVH for an example patient is 
shown in Figure 1.
Follow-up and Toxicity assessment
Patients were assessed at the start of and at 1  month after 
therapy, every 3  months for the first year, and every 6  months 
thereafter. The utilization of alpha-antagonists, oral corticoster-
oids, anticoagulation or antiplatelet therapy, and anti-diarrheal 
therapy was documented at each visit. GI and GU toxicities were 
prospectively documented at follow-up visits using the National 
Cancer Institute Common Terminology Criteria (CTC) version 
4.0 as previously described (27). Specifically, acute toxicity was 
defined as occurring up to the first 6 months after therapy, and 
late toxicity was defined as occurring at 6 months or thereafter.
Grade 1 rectal bleeding was defined as transient and not 
requiring medications for symptomatic management. Grade 
2 rectal bleeding represented bleeding which required a new 
medication (i.e., steroid suppository) or up to two argon plasma 
coagulations (APCs). More than two APC procedures, a blood 
transfusion, or use of hyperbaric oxygen (HBO) was defined 
as grade 3 rectal bleeding. Grade 1 diarrhea was defined as 
transient diarrhea not requiring medical management. Grade 
2 diarrhea was defined as increased stool frequency requiring 
management with anti-diarrheal medication. The development 
of rectal strictures or fistulas was defined as grade 4 GI toxicity. 
Furthermore, because all patients were treated on an institutional 
protocol, all rectal bleeding events were assessed by endoscopy. 
Radiation-induced rectal telangiectasias were graded using the 
Vienna Rectoscopy Score (VRS), with grade 1 defined as a single 
telangiectasia, grade 2 as multiple non-confluent telangiectasias, 
and grade 3 as multiple confluent telangiectasias (28).
TaBle 1 | Patient characteristics and treatment specifics.
Percent patients (n = 108)
age (years): median 74 (55–91)
<60 6
60–69 24
70–79 52
≥80 19
race
White 47
Black 42
Hispanic 3
Asian 2
Other 6
Pre-Tx prostate-specific antigen (ng/ml): 
median 9.1 (0.86–39.8)
≤10 51
>10 and ≤20 34
>20 15
T stage
T1c 46
T2a 12
T2b 28
T2c 13
T3 1
gleason score
6 9
7 51
8 25
9 15
charlson comorbidity index
0–1 75
2–3 23
4 3
risk group (D’amico)
Low 4
Intermediate 42
High 55
hormone therapy
Yes 63
No 37
anti-coagulation/-platelet therapy
Anticoagulation 8
Antiplatelet 48
intensity-modulated radiation therapy 
dose
45 Gy 78
50.4 Gy 19
Other 3
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For GU toxicities, a transient toxicity requiring no new medi-
cations for symptomatic management was considered grade 1. 
The use of a new medication or an increase in the dosage of an 
already-used medication for symptomatic management was con-
sidered grade 2. Grade 3 hematuria, urethral stricture, and urinary 
retention were defined as requiring an outpatient procedure such 
as fulguration, urethral dilation, or transurethral resection of the 
prostate (TURP), respectively. Any toxicity requiring initiation of 
more invasive therapy was defined as grade 4.
statistical analysis
Logistic regression analysis was performed to identify patient 
characteristics associated with an increased risk of late ≥grade 
2 GI toxicity, late ≥grade 2 rectal bleeding, and late grade 3 GU 
toxicity. Statistical analysis was performed using MedCalc soft-
ware (Ostend, Belgium).
resUlTs
From March 2008 to September 2012, 108 prostate cancer 
patients were treated on an institutional IMRT plus SBRT boost 
protocol. The median follow-up was 4.2  years (range 2.4–7.5). 
Patient characteristics are shown in Table 1. The median age was 
74 years (range 55–91). Similar numbers of Caucasians (47%) and 
African-Americans (42%) were treated. Patients were generally 
healthy, with a Charlson comorbidity index of 0–1 in 75%. Eight 
percent were on anticoagulation therapy, and an additional 48% 
were on antiplatelet therapy at the start of radiation therapy. 
The median pre-treatment prostate-specific antigen was 9.1 ng/
ml (range 0.86–39.8 ng/ml). By D’Amico classification, 4% were 
diagnosed with low-, 42% with intermediate-, and 55% with 
high-risk disease. Seventy-eight percent of patients were treated 
with an IMRT dose of 45 Gy in 25 fractions. Sixty-three percent 
received ADT for a median of 6 months (range 3–36 months).
The prevalence of GI and GU toxicities following treatment are 
shown in Tables 2 and 3. The majority of toxicities were observed 
at one specific follow-up appointment and resolved on subsequent 
follow-ups. The most common acute grade 2 GI toxicity was diar-
rhea, with a peak in 7% of patients at 1 month (Table 2). There 
were no acute ≥grade 2 rectal bleeding events. The cumulative 
rate of late ≥grade 2 GI toxicity was 12% (Figure 2), 7% of which 
was due to rectal bleeding and 5% due to diarrhea. Rectal bleed-
ing occurred most commonly at 12 months following radiation 
therapy. Of the seven patients who developed ≥grade 2 bleeding, 
one was on both anticoagulation and antiplatelet therapy, three 
on antiplatelet therapy only, and three on neither therapy. Six of 
these patients were assigned as grade 2 bleeding for requiring one 
or two coagulation procedures, and one was assigned as grade 3 
for undergoing HBO. Further details for patients who developed 
rectal bleeding are shown in Table 4. Of note, logistic regression 
analysis identified no patient characteristics associated with an 
increased risk of late ≥grade 2 GI toxicity or late ≥grade 2 rectal 
bleeding, including use of anticoagulation or antiplatelet therapy 
(data not shown).
A total of 42 patients underwent a colonoscopy during the 
follow-up period either to assess the etiology of rectal bleeding or 
for routine cancer screening. Radiation-induced telangiectasias 
were noted in 16 cases and were graded as VRS grade 1 in 3 
patients, grade 2 in 10 patients, and grade 3 in 3 patients. One 
patient was noted to have an incidental grade 1 ulcer, which 
spontaneously resolved on subsequent colonoscopy. Importantly, 
no rectal strictures or fistulas (grade 4 toxicity) were noted.
The most common acute grade 2 GU toxicity was urinary 
retention relieved by medical management, peaking at 1 month 
(Table 3). One patient with acute urinary retention underwent 
a TURP and was classified as grade 3. There were no ≥grade 2 
TaBle 3 | Prevalence of cTc graded genitourinary (gU) toxicities at each 
follow-up to 36 months.
Month 1 3 6 9 12 18 24 30 36
Toxicity grade % % % % % % % % %
Hematuria 0 97 98 96 97 95 92 94 95 93
1 3 2 4 3 5 6 5 3 1
2 0 0 0 0 0 0 0 0 4
3 0 0 0 0 0 2 1 1 1
Dysuria 0 88 91 91 91 86 95 93 92 93
1 12 9 9 9 12 5 6 7 7
2 0 0 0 0 2 0 1 1 0
Incontinence 0 77 85 86 80 82 83 79 68 77
1 21 13 14 18 16 16 21 29 19
2 2 2 0 2 2 1 0 3 4
Urinary 
frequency/
urgency
0 53 58 73 71 69 69 70 51 51
1 45 41 27 28 28 30 29 50 49
2 2 1 0 1 3 1 1 0 0
Retention 0 62 69 71 66 71 67 62 56 59
1 23 23 18 23 16 20 23 34 32
2 15 8 10 11 12 12 14 10 9
3 1 0 1 0 0 1 0 0 0
Highest GU 0 26 37 48 42 46 48 40 34 39
1 55 53 40 44 38 36 45 52 44
2 18 10 10 15 16 14 14 12 16
3 1 0 1 0 0 3 1 1 1
TaBle 2 | Prevalence of cTc graded gastrointestinal (gi) toxicities at 
each follow-up to 36 months.
Month 1 3 6 9 12 18 24 30 36
Toxicity grade % % % % % % % % %
Diarrhea 0 75 82 83 74 79 95 78 77 79
1 19 14 13 23 19 5 20 22 21
2 7 3 4 3 2 0 2 1 0
Proctitis 0 90 96 95 95 93 96 95 96 93
1 10 4 5 5 7 4 5 4 7
2 0 0 0 0 0 0 0 0 0
Rectal bleeding 0 87 96 87 85 83 84 81 87 87
1 13 4 13 15 12 14 18 13 12
2 0 0 0 0 4 2 1 0 1
3 0 0 0 0 1a 0 0 0 0
Highest GI 0 62 76 72 66 64 68 65 68 68
1 31 21 24 31 31 29 32 31 31
2 7 3 4 3 4 3 3 1 1
3 0 0 0 0 1 0 0 0 0
aPatient with non-healing ulcer required hyperbaric oxygen and was assigned as grade 
3 toxicity. FigUre 2 | cumulative late ≥grade 2 gastrointestinal (gi) toxicity.
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hematuria events acutely. The cumulative rate of late ≥grade 2 
GU toxicity was 40%. The majority of these toxicities were due 
to obstructive or irritative symptoms requiring medical manage-
ment with alpha-antagonists and/or anti-muscarinics. In fact, the 
cumulative rate of late ≥grade 3 GU toxicity was much lower at 
6% (Figure  3), 4% due to hematuria and 2% due to retention. 
The most common areas of radiation cystitis noted on cystos-
copy were the bladder neck, trigone, or lateral walls. Of the four 
patients who experienced bleeding, two were on antiplatelet 
therapy and none were on anticoagulation therapy. One of these 
patients with recurrent bleeding secondary to vigorous physical 
activity also elected to proceed with HBO. Details for patients 
with hematuria are provided in Table 5. Of the two patients who 
underwent a TURP for late urinary retention, one had a long 
history of benign prostatic hypertrophy and prostatitis with two 
prior TURP procedures. This patient also elected to undergo 
HBO. No patient developed a urethral stricture or any grade 4 
or 5 GU toxicity. Logistic regression also identified no patient 
characteristics associated with an increased risk of late grade 3 
GU toxicity.
DiscUssiOn
This study aimed to assess the safety of performing IMRT with 
SBRT boost for unfavorable clinically localized prostate cancer. 
SBRT boost was chosen for this study due to the potential radio-
biologic benefits of hypofractionation (29) as well as the ease of 
the treatment modality, especially for the elderly prostate cancer 
patient population.
Intensity-modulated radiation therapy plus SBRT boost was 
generally well tolerated with minimal acute toxicity (Tables 2 and 
3). Cumulative late ≥grade 2 and ≥grade 3 GU toxicities were 
observed in 40 and 6% of patients, respectively. It should be noted 
that the seemingly high rate of grade 2 GU toxicity was due to 
use of alpha-antagonists or corticosteroids for transient irritative 
or obstructive symptoms. In fact, the prevalence of any grade 2 
GU toxicity was 10–16% after the 3-month time period (Table 3). 
It is encouraging that only 4% of patients developed hematuria 
requiring fulguration, and only 2% developed retention requir-
ing a TURP. In comparison, published brachytherapy boost 
studies have reported late GU toxicity rates of 8–31% (≥grade 
2) and 3–18% (≥grade 3) (Table  6) (14–16, 30). Importantly, 
FigUre 3 | cumulative late ≥grade 3 genitourinary (gU) toxicity.
TaBle 4 | Patients with late ≥grade 2 rectal bleeding.
Patient age antiplatelets anticoagulants Time to bleed (months) Vienna rectoscopy score grade argon plasma coagulation
1 72 N/A N/A 12, 18, and 24 2 Yes
2 79 Aspirin (unknown dose) N/A 12 2 Yes
3 82 Aspirin (81 mg) N/A 12 3 Yes
4a 69 Aspirin (81 mg) N/A 12 2 No
5 75 Aspirin (325 mg) Apixaban 12 2 Yes
6 66 N/A N/A 18 3 Yes
7 65 N/A N/A 36 2 Yes
aOne patient with a non-healing rectal ulcer elected to have treatment with hyperbaric oxygen and was assigned as grade 3.
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the ASCENDE-RT trial reported a cumulative late ≥grade 3 GU 
toxicity rate of 18% at 6  years for patients undergoing a LDR 
boost, most commonly due to urethral strictures, urinary reten-
tion, or incontinence (30). Our 6% cumulative rate of clinically 
significant late GU toxicity is lower than that reported in this 
trial, though longer follow-up will be necessary to confirm our 
results. Other institutions using the SBRT boost technique have 
reported a 0–2.3% rate of late ≥grade 3 GU toxicities, which are 
comparable to our results reported here (20–23).
Our study reported overall modest rates of GI toxicity, with 
a 12% cumulative incidence of late ≥grade 2 GI toxicity, 7% 
late ≥grade 2 rectal bleeding, and 1% late grade 3 bleeding. In 
comparison, we have previously reported a 1.5% rate of late 
≥grade 2 rectal bleeding with SBRT alone (34). Other studies 
have reported a somewhat lower 1–3% rate of late ≥grade 2 rectal 
bleeding with brachytherapy boost (16, 30). Moreover, 16 (15%) 
of our patients were noted to have telangiectasias, 3 of which were 
multiple confluent telangiectasias (VRS grade 3). No VRS grade 3 
telangiectasias were previously noted with SBRT alone (34).
Despite overall higher rates of GI and GU toxicity compared 
to SBRT alone, a sample DVH of the combined SBRT and IMRT 
plans for one patient (Figure 1) demonstrates that the bladder 
volume receiving 55 and 70 Gy and the rectal volumes receiving 
50 and 70 Gy in 2 Gy equivalents are well below the Radiation 
Therapy Oncology Group recommendations (35). This suggests 
that the wide IMRT margins and the resulting near-maximal dose 
at the bladder neck and anterior rectal wall likely contribute to 
bleeding events, and future dosimetric studies will need to define 
the appropriate dose-constraints for patients treated with this 
approach.
Previously, we reported that IMRT with SBRT boost resulted 
in minimal impact on long-term bowel QOL (19), a finding which 
is seemingly discordant with late toxicity results shown here. A 
similar phenomenon has been seen following IMRT monotherapy 
(31, 36). Several explanations are possible. For example, the most 
common toxicities—rectal bleeding, hematuria, and urinary 
obstruction—were transient and resolved by the following time 
point (37). Also, bleeding likely renders a less bothersome impact 
on QOL than frequency and urgency (38). Lastly, effects on QOL 
are reported as temporal changes in mean scores derived from 
the expanded prostate cancer index composite-26 questionnaire 
while the CTCAE toxicity scoring system focuses on individual 
uncommon events (39).
Analysis of such uncommon events is still necessary, since 
telangiectasias or ulcers may be a precursor lesion for a fistula. 
While a small percentage of telangiectasias progress to fistulas 
and often do so after multiple invasive procedures (40, 41), such 
a late toxicity can nonetheless be devastating for a patient. Thus, 
it is encouraging that only three of our patients required two APC 
procedures, with no reportable fistulas to date. Though fistulas 
most often develop within the first 3 years (40), longer follow-up 
is still necessary to detect a potential late occurrence.
What is the minimum follow-up time to assess late toxicity 
after prostate SBRT such that clinically meaningful events are 
captured fully without undue delay in reporting these important 
outcomes? For the majority of patients, rectal bleeding occurred 
at the 1- to 1.5-year time point and resolved after one to two APC 
procedures, suggesting that a 3-year median follow-up likely cap-
tures most rectal bleeding events. However, hematuria occurred 
starting at 18 months post-treatment and continued to present as 
late as 36 months, emphasizing the necessity of long-term follow-
up for such patients. While no fistulas or strictures of the urethra 
have been observed, longer follow-up may be necessary to reveal 
such toxicity as well.
Our encouraging rates of GI and GU toxicity are consistent 
with results from other institutions using this modality (20–23), 
though minor differences in technique do exist. For instance, 
the three largest published series included pelvic lymph nodes 
in the external beam radiotherapy portion (20–23) and utilized 
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TaBle 5 | Patients with late grade 3 hematuria.
Patient age Prior transurethral resection 
of the prostate
antiplatelets Time to bleeding 
(months)
areas of rT changes on cystoscopy Fulguration
1a 65 No Aspirin (81 mg) 18, 36 Left lateral wall, trigone, and posterior bladder neck Yes
2 68 No N/A 18 Base of bladder Yes
3 73 No Aspirin (unknown dose) 24 All areas except dome Yes
4 79 No N/A 30 Bladder neck and posterior wall Yes
No patient was on anticoagulation therapy.
aPatient elected to have hyperbaric oxygen therapy.
TaBle 6 | summary of late ≥grade 2 or 3 toxicities reported for various techniques, including iMrT + sBrT boost.
author institution/trial Technique Dose (gy) Median 
follow-up 
(years)
Pts gr 2 
genitourinary 
(gU) (%)
gr 3 
gU 
(%)
gr 2 
gastrointestinal 
(gi) (%)
gr 
3 gi 
(%)
Zelefsky et al. (6) MSKCC IMRT/IGRT 86.4 2.8 186 10.4 – 1.0 –
IMRT/no IGRT 190 20 – 1.6 –
Michalski et al. (31) Radiation Therapy 
Oncology Group 
(RTOG) 0126
3D-CRT 79.2 4.6 491 13.4 2.5 22 5.1
IMRT 3.5 257 7.8 1.9 15.1 2.6
Mariados et al. (32) PIVOT IMRT/No spacer 79.2 1.25 73 4.2 – 1.4 –
IMRT/spacer 149 6.8 0
King et al. (33) UCLA/Stanford SBRT (5 fxns) 36.25 2.7 67 8.8 3.5 2 0
Chen et al. (27) Georgetown SBRT (5 fxns) 35–36.25 2.3 100 31 1 1 0
Khor et al. (13) Melbourne, Australia HDR boost (3 fxns) + EBRT 19.5 + 46 5 344 16.8a 11.8a – –
Hoskin et al. (15) UK HDR boost (2 fxns) + EBRT 
(13 fxns)
17 + 35.75 7.1 110 31b – 7b –
Hsu et al. (16) RTOG 0321 HDR boost (2 fxns) + EBRT 19 + 45 2.5 112 7.1 2.7 2.7 0.9
Rodda et al. (30) ASCENDE-RT LDR boost + EBRT 115 6.5 198 – 18 – 9
EBRT 78 200 8 4
Katz and Kang (21) Winthrop SBRT boost (3 fxns) + 3D-CRT (19 to 21) + 45 5 45 4.6 2.3 13.3 –
Lin et al. (20) Taiwan SBRT boost (3 fxns) + VMAT 21 + 45 3.5 41 3–11c 0 0 0
Anwar et al. (23) UCSF SBRT boost (2 fxns) + SIB (9.5 to 
10.5) + 45
3.6 48 27 2 0 0
Paydar et al. (24) Georgetown SBRT boost + IMRT 19.5 + (45 to 
50.4)
4.2 108 40 6 12 1
IMRT, intensity-modulated radiation therapy; IGRT, image-guided radiation therapy; 3D-CRT, 3D-conformal radiation therapy; SBRT, stereotactic body radiation therapy; HDR, high 
dose rate; LDR, low dose rate; EBRT, external beam radiation therapy; VMAT, volumetric arc therapy; SIB, simultaneous integrated boost.
aUrethral stricture rates.
bSevere toxicity per the Dische scale.
c0–11% toxicity rates in late follow-up period with cumulative rates not reported.
a 3D-conformal (21, 22), volumetric arc therapy (20), or simulta-
neous integrated boost (23) technique for dose delivery. It should 
be emphasized that no overall survival benefit has been dem-
onstrated thus far for the treatment of pelvic nodes in high-risk 
disease (42, 43), and inclusion of pelvic nodes remains a matter of 
controversy. Furthermore, different dose-fractionation schemas 
as well as PTV margins were used for the SBRT portion in each 
study. For instance, Anwar et al. utilized PTV margins of 0 mm 
posteriorly and 2 mm elsewhere (23). Such smaller margins may 
have contributed to the lower rates of overall toxicity, with only 
one late grade 3 GU and no grade 3 GI toxicities reported.
These low toxicity rates question the use of larger PTV 
margins or IMRT at all. Even with dose-escalated external beam 
radiotherapy for clinically localized prostate cancer, most failures 
occur locally within the prostate or adjacent seminal vesicles 
(44). However, surgical pathology studies report a median ECE 
of 0.5–2.4 mm and a 4–5 mm margin necessary to cover ≥90% of 
the ECE (45–48). Our treatment planning studies have further-
more demonstrated potential under-dosing of the posterior pros-
tate without adequate PTV margin (49). Thus, the appropriate 
planning technique remains an ongoing debate, and long-term 
outcomes will identify the optimal combinatorial approach as 
well as target volume.
One approach to maintaining adequate posterior margins 
while reducing the risk of rectal bleeding is to place a tissue 
equivalent spacer in the perirectal space prior to treatment. This 
approach can increase percent target coverage of the PTV while 
simultaneously reducing the rectal volume receiving near-max-
imal dose (50). In fact, a recent prospective trial demonstrated 
a statistically significant reduction in late rectal toxicity from 
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